Feldman, S. R., Narbutt, J., Girolomoni, G., Brzezicki, J., Reznichenko, N., Zegadło-Mylik, M. A., . . . Rho, Y. H. (2024). A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis. Journal of the American Academy of Dermatology, 91(3), 440-448.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita Chicago Style (17a ed.)
Feldman, Steven R., et al. "A Randomized, Double-blind, Phase III Study Assessing Clinical Similarity of SB17 (proposed Ustekinumab Biosimilar) to Reference Ustekinumab in Subjects with Moderate-to-severe Plaque Psoriasis."
Journal of the American Academy of Dermatology 91, no. 3 (2024): 440-448.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita MLA (9a ed.)
Feldman, Steven R., et al. "A Randomized, Double-blind, Phase III Study Assessing Clinical Similarity of SB17 (proposed Ustekinumab Biosimilar) to Reference Ustekinumab in Subjects with Moderate-to-severe Plaque Psoriasis."
Journal of the American Academy of Dermatology, vol. 91, no. 3, 2024, pp. 440-448.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Precaución: Estas citas no son 100% exactas.